Follow-up of [11C]PIB uptake and brain volume in patients with alzheimer disease and controls

Neurology

Volumn 73, Issue 15, 2009, Pages 1186-1192

  Scheinin, Noora M ^a   Aalto, S ^a,b   Koikkalainen, J ^c   Lotjonen J ^c   Karrasch, M ^b   Kemppainen, N ^a,d   Viitanen, M ^e,f   Nagren K ^a,g   Helin, S ^a   Scheinin, M ^a   Rinne, J O ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b ÅBO AKADEMI UNIVERSITY   (Finland)

^c VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e TURKU CITY HOSPITAL   (Finland)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; PITTSBURGH COMPOUND B 11 C; TRACER; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HIPPOCAMPUS; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; MORPHOMETRICS; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; TEMPORAL CORTEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID; ANILINE COMPOUNDS; BRAIN; CARBON RADIOISOTOPES; CASE-CONTROL STUDIES; COGNITION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; ORGAN SIZE; THIAZOLES;

EID: 70350164263     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181bacf1b     Document Type: Article

References (24)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer?s disease: progress and problems on the road to therapeutics. Science 2002;297:353-356.
2. Ikonomovic MD, Klun WE, Abrahamson EE, et al. Post mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer?s disease. Brain 2008;131: 1630-1645.
3. Kemppainen NM, Aalto S, Wilson IA, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007;68:1603-1606.
4. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer?s disease with Pittsburgh compound-B. Ann Neurol 2004;55:306-319.
5. Mintun MA, LaRossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-452.
6. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68:1718-1725.
7. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer?s disease. Brain 2006;129:2856-2866.
8. Rusinek H, De Santi S, Frid D, et al. Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology 2003; 229:691-696.
9. Silbert LC, Quinn JF, Moore MM, et al. Changes in pre-morbid brain volume predict Alzheimer?s disease pathology. Neurology 2003;61:487-492.
10. Archer HA, Edison P, Brooks DJ, et al. Amyloid load and cerebral atrophy in Alzheimer?s disease: an 11C-PIB positron emission tomography study. Ann Neurol 2006; 60:145-147.
11. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer?s disease and amnestic mild cognitive impairment. Brain 2008;131:665-680.
12. Frisoni GB, Lorenzi M, Caroli A, et al. In vivo mapping of amyloid toxicity in Alzheimer?s disease. Neurology 2009; 72:1504-1511.
13. Kemppainen NM, Aalto S, Wilson IA, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006;67:1575-1580.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer?s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer?s Disease. Neurology 1984;34: 939-944.
15. Collie A, Maruff P. The neuropsychology of preclinical Alzheimer?s disease and mild cognitive impairment. Neu-rosci Biobehav Rev 2000;24:365-374.
16. Friston KJ, Worsley KJ, Poline JB, Frith CD, Franckowiak RSJ. Statistical parametric maps in functional brain imaging: a general approach. Hum Brain Map 1995;2:189-210.
17. Meyer JH, Gunn RN, Myers R, Grasby PM. Assessment of spatial normalization of PET ligand images using ligand-specific templates. Neuroimage 1999;9:545-553.
18. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15:273-289.
19. Mathis CA, Lopresti BJ, Klunk WE. Impact of amyloid imaging on drug development in Alzheimer?s disease. Nucl Med Biol 2007;34:809-822.
20. Kemppainen NM, Aalto S, Karrasch M, et al. Cognitive reserve hypothesis: Pittsburgh compound B and fluorode-oxyglucose positron emission tomography in relation to education in mild Alzheimer?s disease. Ann Neurol 2008; 63:112-118.
21. Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005; 46:1959-1972.
22. Aalto S, Scheinin NM, Kemppainen NM, et al. Reprodu-cibility of automated simplified voxel-based analysis of PET amyloid ligand [(11)C]PIB uptake using 30-min scanning data. Eur J Nucl Med Mol Imaging 2009 Jun 4.
23. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008;65:1509-1517.
24. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer?s disease. Brain 2007;130: 2837-2844.